Can Rexulti Be Stopped Abruptly When Switching to Another Antipsychotic?
No, brexpiprazole (Rexulti) should NOT be stopped abruptly when switching to another antipsychotic—use gradual cross-titration instead, informed by the drug's long half-life and receptor profile.
Switching Strategy Based on Pharmacokinetics
While brexpiprazole has a relatively long elimination half-life (approximately 91 hours), which theoretically allows for "auto-tapering" 1, the most recent international guidelines explicitly recommend against abrupt switching. The 2025 INTEGRATE guidelines state that "antipsychotic switching should involve gradual cross-titration informed by the half-life and receptor profile of each medication" 2. This takes precedence over the theoretical pharmacokinetic considerations.
Why Cross-Titration Matters for Brexpiprazole
The 2026 ASCP consensus guidelines note an important caveat: "Cross-tapering is advisable when switching within-class from a drug with anticholinergic properties (eg, olanzapine, quetiapine) to one without anticholinergic properties (eg, aripiprazole, risperidone) to avoid cholinergic rebound" 1. While brexpiprazole itself has minimal anticholinergic activity, the direction of your switch matters:
- If switching FROM brexpiprazole TO another antipsychotic: A gradual taper is still recommended to minimize withdrawal phenomena and maintain symptom control
- If switching TO brexpiprazole FROM an anticholinergic antipsychotic: Cross-tapering is essential to prevent cholinergic rebound
Practical Switching Protocol
Based on real-world evidence from Japanese clinical practice 3, here's the recommended approach:
Week 1-2:
- Start brexpiprazole at 1 mg/day
- Continue full dose of current antipsychotic
Week 3-4:
- Increase brexpiprazole to 2 mg/day at start of week 3
- Begin tapering current antipsychotic gradually from start of week 3
- Discontinue previous antipsychotic completely by end of week 4
Week 5-8:
- Titrate brexpiprazole up to 4 mg/day based on clinical response
- Monitor closely for symptom exacerbation or adverse effects
Discontinuation Rates by Strategy
Real-world data shows the importance of gradual switching 3:
- Overall 8-week discontinuation rate: 17.0%
- Discontinuation from adverse events: 5.5%
- Patients switching from aripiprazole had only 4.9% discontinuation vs. 25.4% from other antipsychotics
This suggests that switching between dopamine partial agonists may be safer, but gradual cross-titration remains the standard approach.
Critical Caveats and Risk Factors
High-Risk Populations Requiring Extra Caution
Treatment-resistant schizophrenia (TRS): Patients with TRS have significantly higher switching failure rates to brexpiprazole 4. Monitor these patients weekly during the switch period.
Dopamine supersensitivity psychosis: Interestingly, recent evidence suggests brexpiprazole may be switched more safely than aripiprazole in patients with dopamine supersensitivity 4. However, this still requires gradual cross-titration, not abrupt switching.
Previous olanzapine use: Serious adverse events leading to discontinuation were more common when switching from olanzapine 3. Use extra caution and slower titration in these patients.
Common Adverse Events During Switching
The most frequent adverse events during the switching period include 3:
- Akathisia (5.5%)—the most common extrapyramidal symptom
- Insomnia (6.5%)
- Headache (5.5%)
- Worsening schizophrenia symptoms (9.0%)
When Abrupt Discontinuation Might Be Considered
The 2026 ASCP guidelines acknowledge that "medications with a long terminal elimination half-life (eg, fluoxetine, vortioxetine, cariprazine, aripiprazole) or long-acting injectable antipsychotics generally can be abruptly stopped without the need for a downward dose titration because they will auto-taper" 1. However, this achieved only 81% consensus with just 38% high confidence among experts.
In clinical practice, reserve abrupt discontinuation only for:
- Urgent medical situations (severe adverse reactions, anticholinergic toxicity)
- When the patient absolutely refuses gradual tapering
- When switching between very similar dopamine partial agonists (e.g., aripiprazole to brexpiprazole) in stable patients
Even in these scenarios, close monitoring for symptom exacerbation is mandatory.
Monitoring During the Switch
Weekly assessments for the first 4 weeks should include:
- Positive and negative symptom severity
- Extrapyramidal symptoms, especially akathisia
- Vital signs and metabolic parameters
- Patient adherence and tolerability
Obtain collateral information from caregivers about behavioral changes, as patients may have limited insight into symptom worsening 1.
The evidence strongly supports gradual cross-titration over abrupt switching for brexpiprazole, despite its long half-life. This approach minimizes discontinuation rates, adverse events, and symptom exacerbation while maintaining therapeutic continuity 2.